JP2019515646A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515646A5 JP2019515646A5 JP2018544554A JP2018544554A JP2019515646A5 JP 2019515646 A5 JP2019515646 A5 JP 2019515646A5 JP 2018544554 A JP2018544554 A JP 2018544554A JP 2018544554 A JP2018544554 A JP 2018544554A JP 2019515646 A5 JP2019515646 A5 JP 2019515646A5
- Authority
- JP
- Japan
- Prior art keywords
- binding member
- seq
- member according
- sequence
- cdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16020057.2 | 2016-02-25 | ||
| EP16020057 | 2016-02-25 | ||
| PCT/EP2017/054367 WO2017144681A1 (en) | 2016-02-25 | 2017-02-24 | Binding members to pd-l1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515646A JP2019515646A (ja) | 2019-06-13 |
| JP2019515646A5 true JP2019515646A5 (enExample) | 2020-04-09 |
| JP7080819B2 JP7080819B2 (ja) | 2022-06-06 |
Family
ID=55446573
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544554A Expired - Fee Related JP7080819B2 (ja) | 2016-02-25 | 2017-02-24 | Ｐｄ－ｌ１に対する結合メンバー |
| JP2018545230A Expired - Fee Related JP7082574B2 (ja) | 2016-02-25 | 2017-02-24 | 免疫療法用改変細胞 |
| JP2022088103A Pending JP2022116230A (ja) | 2016-02-25 | 2022-05-30 | 免疫療法用改変細胞 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018545230A Expired - Fee Related JP7082574B2 (ja) | 2016-02-25 | 2017-02-24 | 免疫療法用改変細胞 |
| JP2022088103A Pending JP2022116230A (ja) | 2016-02-25 | 2022-05-30 | 免疫療法用改変細胞 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11434294B2 (enExample) |
| EP (3) | EP4086285A1 (enExample) |
| JP (3) | JP7080819B2 (enExample) |
| KR (2) | KR20180111870A (enExample) |
| CN (3) | CN108699153B (enExample) |
| AU (2) | AU2017223846A1 (enExample) |
| BR (2) | BR112018067698A2 (enExample) |
| CA (2) | CA3014001A1 (enExample) |
| ES (1) | ES2903408T3 (enExample) |
| RU (2) | RU2018128464A (enExample) |
| SG (2) | SG11201807188VA (enExample) |
| WO (2) | WO2017144681A1 (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| GB201506642D0 (en) | 2015-04-20 | 2015-06-03 | Ucl Business Plc | T cell receptor |
| CA3001131A1 (en) | 2015-11-02 | 2017-05-11 | Five Prime Therapeutics, Inc. | Cd80 extracellular domain polypeptides and their use in cancer treatment |
| EP4086285A1 (en) * | 2016-02-25 | 2022-11-09 | Cell Medica Switzerland AG | Binding members to pd-l1 |
| TWI822521B (zh) | 2016-05-13 | 2023-11-11 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| GB201617714D0 (en) * | 2016-10-19 | 2016-11-30 | Ucl Business Plc | T Cell receptor |
| MD3551221T2 (ro) | 2016-12-08 | 2022-04-30 | Immatics Biotechnologies Gmbh | Noi receptori de celule T și imunoterapie cu utilizarea acestora |
| CA3047313A1 (en) | 2016-12-16 | 2018-06-21 | B-Mogen Biotechnologies, Inc. | Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods |
| US11278570B2 (en) | 2016-12-16 | 2022-03-22 | B-Mogen Biotechnologies, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
| CN117442719A (zh) | 2017-02-21 | 2024-01-26 | 瑞泽恩制药公司 | 用于治疗肺癌的抗pd-1抗体 |
| KR20190141695A (ko) | 2017-04-13 | 2019-12-24 | 센티 바이오사이언시스, 인코포레이티드 | 병용 암 면역요법 |
| CN110546509A (zh) | 2017-04-28 | 2019-12-06 | 戊瑞治疗有限公司 | 用cd80细胞外结构域多肽进行治疗的方法 |
| AU2018393110B2 (en) | 2017-12-20 | 2023-04-27 | Poseida Therapeutics, Inc. | VCAR compositions and methods for use |
| CN111684061B (zh) | 2018-01-19 | 2024-07-30 | 美天施生物科技有限两合公司 | 表达嵌合抗原受体的调节性t细胞 |
| WO2019166650A1 (en) | 2018-03-02 | 2019-09-06 | Cdr-Life Ag | Trispecific antigen binding proteins |
| CN112424225B (zh) * | 2018-03-29 | 2023-08-11 | 桂林三金药业股份有限公司 | 抗pd-l1抗体及其用途 |
| EP3801771B1 (en) * | 2018-06-04 | 2024-10-23 | Diatheva S.r.l. | Anti-cd99 diabody or igg antibody and uses thereof |
| WO2019246486A2 (en) | 2018-06-21 | 2019-12-26 | B-Mogen Biotechnologies, Inc. | ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS |
| WO2020005003A1 (ko) * | 2018-06-29 | 2020-01-02 | 주식회사 와이바이오로직스 | Lag-3에 특이적으로 결합하는 단클론항체 및 이의 용도 |
| CN112672753B (zh) | 2018-07-09 | 2025-07-08 | 普瑞赛格恩公司 | 融合构建体及其使用方法 |
| US12698340B2 (en) | 2018-10-01 | 2026-08-04 | Adicet Therapeutics, Inc. | Compositions and methods regarding engineered and non-engineered γδ T-cells for treatment of solid tumors |
| BR112021006182A2 (pt) | 2018-10-01 | 2021-06-29 | Adicet Bio, Inc. | composições e métodos relativos a células t¿d,d engenheiradas e não engenheiradas para tratamento de tumores hematológicos |
| US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| CA3116138A1 (en) | 2018-10-17 | 2020-04-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| SG11202105975SA (en) * | 2018-12-06 | 2021-07-29 | Guangdong Tcrcure Biopharma Technology Co Ltd | Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints |
| WO2020123964A1 (en) | 2018-12-13 | 2020-06-18 | Labyrx Immunologic Therapeutics (Usa) Limited | Labyrinthin-based peptides for cancer immunotherapies and uses thereof |
| US20220144960A1 (en) | 2018-12-26 | 2022-05-12 | Nanjing Legend Biotech Co., Ltd. | Cd30-binding moieties, chimeric antigen receptors, and uses thereof |
| CN109652379B (zh) * | 2018-12-29 | 2022-08-16 | 博生吉医药科技(苏州)有限公司 | Cd7嵌合抗原受体修饰的nk-92mi细胞及其应用 |
| CN111454358A (zh) * | 2019-01-18 | 2020-07-28 | 四川科伦博泰生物医药股份有限公司 | 一种嵌合抗原受体及其应用 |
| GB201900858D0 (en) * | 2019-01-22 | 2019-03-13 | Price Nicola Kaye | Receptors providing targeted costimulation for adoptive cell therapy |
| MX428176B (es) * | 2019-01-28 | 2025-11-13 | Xyphos Biosciences Inc | Ligandos nkg2d no naturales modificados que entregan selectivamente moléculas heterólogas unidas a receptores nkg2d no naturales en células car. |
| AU2020224137B2 (en) | 2019-02-22 | 2026-01-08 | Five Prime Therapeutics, Inc. | CD80 extracellular domain-Fc fusion proteins for treating PD-L1 negative tumors |
| EP3934666A1 (en) * | 2019-03-08 | 2022-01-12 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| MX2021011494A (es) * | 2019-03-26 | 2021-12-15 | Univ California | Células t modificadas con el receptor de antígeno quimérico (t car) para el tratamiento de cánceres hematológicos y tumores sólidos. |
| CN110402892A (zh) * | 2019-04-30 | 2019-11-05 | 梁廷波 | 选择性敲除胰腺上皮细胞程序性死亡配体1分子的自发胰腺癌小鼠模型的建立方法 |
| MX2021013272A (es) | 2019-05-03 | 2021-11-17 | Five Prime Therapeutics Inc | Formulaciones farmaceuticas que contienen proteinas de fusion fc de dominio extracelular de cd80. |
| CN114174325A (zh) * | 2019-06-04 | 2022-03-11 | 恩卡尔塔公司 | 用于免疫疗法的工程化自然杀伤细胞和工程化t细胞的组合 |
| CN112079924B (zh) * | 2019-06-12 | 2024-02-06 | 苏州工业园区唯可达生物科技有限公司 | Pd-l1靶向结合剂及其用途 |
| MA56467A (fr) * | 2019-07-02 | 2022-05-11 | Telix Int Pty Ltd | Anticorps dirigés contre caix avec une affinité réduite pour le récepteur fc néonatal |
| WO2021057906A1 (zh) * | 2019-09-25 | 2021-04-01 | 科济生物医药（上海）有限公司 | 表达il-15的免疫效应细胞 |
| US20210128710A1 (en) * | 2019-11-04 | 2021-05-06 | Inovio Pharmaceuticals, Inc. | Combination therapy to treat brain cancer |
| RU2733430C1 (ru) * | 2019-11-19 | 2020-10-01 | Общество с ограниченной ответственностью «Реал Таргет» | Создание конъюгатов gd2-специфичных антител и фрагментов gd2-специфичных антител с препаратами |
| CN110760007B (zh) * | 2019-11-21 | 2022-08-26 | 博生吉医药科技(苏州)有限公司 | Cd7-car-t细胞及其制备和应用 |
| CA3159308A1 (en) * | 2019-12-02 | 2021-06-10 | Wayne A. Marasco | Antibodies against pd-l1 and methods of use thereof |
| WO2021130535A2 (en) * | 2019-12-28 | 2021-07-01 | Shanghai Cell Therapy Group Company Co., Ltd. | Cell expressing immune modulatory molecules and system for expressing immune modulatory molecules |
| EP3878858A1 (en) * | 2020-03-11 | 2021-09-15 | Affilogic | Variants of sac7d and their use in cancer therapy |
| EP4123021A4 (en) * | 2020-03-23 | 2024-05-15 | Curigin Co.,Ltd. | STRUCTURE OF AN ONCOLYTIC VIRUS WITH BISPECIFIC NUCLEIC ACID MOLECULE |
| CA3171795A1 (en) * | 2020-04-06 | 2021-10-14 | Jintang DU | Modular synthetic receptors and methods of use |
| IL298279A (en) * | 2020-04-17 | 2023-01-01 | Council Queensland Inst Medical Res | Immune cells with enhanced function |
| US20230312740A1 (en) * | 2020-05-14 | 2023-10-05 | Virtuoso Binco, Inc. | Humanized cd38 and icam1 antibodies and uses thereof |
| WO2021252654A1 (en) * | 2020-06-11 | 2021-12-16 | Innovative Cellular Therapeutics Holdings, Ltd. | Cell/gene therapies targeting mage-a4 peptide |
| CN115916828A (zh) * | 2020-06-25 | 2023-04-04 | 普洛迈博生物技术公司 | Pd-l1-特异性抗体和抗pd-l1-car-t细胞 |
| US12194094B2 (en) | 2020-07-10 | 2025-01-14 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| EP4240380A4 (en) * | 2020-11-04 | 2024-10-16 | Senti Biosciences, Inc. | PROTEIN PAYLOAD RELEASE |
| CN112375743A (zh) * | 2020-11-20 | 2021-02-19 | 山东省医学科学院附属医院 | 一种分泌型靶向her2抗原的嵌合抗原受体t细胞及其应用 |
| EP4251190A4 (en) * | 2020-11-30 | 2024-10-23 | Fred Hutchinson Cancer Center | PD-L1-BINDING PEPTIDES, PEPTIDE COMPLEXES AND METHODS OF USE THEREOF |
| BR112023016706A2 (pt) * | 2021-02-19 | 2023-10-31 | Seoul Nat Univ R&Db Foundation | Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo |
| WO2022219155A1 (en) * | 2021-04-15 | 2022-10-20 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz Gemeinschaft | T-cell receptors specific for both rac1- and rac2-derived mutated epitopes |
| CN113234152B (zh) * | 2021-06-03 | 2023-05-02 | 天津科技大学 | 程序性死亡受体-配体1(pd-l1)特异性结合多肽及应用 |
| JP2024527537A (ja) * | 2021-07-01 | 2024-07-25 | 寧波茂行生物医薬科技有限公司 | Ｇｄ２を標的とするユニバーサルｃａｒ－ｔ細胞及びその製造方法並びに使用 |
| US20250179196A1 (en) * | 2021-07-30 | 2025-06-05 | Janssen Biotech, Inc. | Materials and methods of making or using il-23r binding proteins |
| WO2023019240A2 (en) | 2021-08-13 | 2023-02-16 | Inovio Pharmaceuticals Inc. | Combination therapy to treat brain cancer |
| WO2023072043A1 (zh) * | 2021-10-26 | 2023-05-04 | 正大天晴药业集团股份有限公司 | 治疗肿瘤的联用药物 |
| CN116410331B (zh) * | 2021-12-31 | 2024-01-30 | 合源生物科技(天津)有限公司 | 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用 |
| EP4469069A4 (en) * | 2022-01-28 | 2026-05-06 | Univ North Carolina Chapel Hill | T LYMPHOCYTES, NATURAL KILLERS, AND THEIR METHODS OF USE |
| CN118005806B (zh) * | 2024-02-08 | 2026-01-30 | 北京市眼科研究所 | 嵌合抗原受体、人多能干细胞分化的表达嵌合抗原受体的小胶质细胞及其应用 |
| CN120518751B (zh) * | 2025-07-23 | 2025-09-19 | 中国人民解放军军事科学院军事医学研究院 | 抗人4型腺病毒特异性纳米抗体lum44及在抗病毒治疗中的应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4237113B4 (de) | 1992-11-03 | 2006-10-12 | "Iba Gmbh" | Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| DE10113776B4 (de) | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins |
| ATE524495T1 (de) | 2001-07-31 | 2011-09-15 | Ono Pharmaceutical Co | Pd-1-spezifische substanz |
| CN102093477B (zh) | 2002-05-22 | 2014-02-26 | 艾斯巴技术-诺华有限责任公司 | 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法 |
| GB0328363D0 (en) | 2003-12-06 | 2004-01-14 | Imp College Innovations Ltd | Therapeutically useful molecules |
| EP1791865B1 (en) | 2004-06-29 | 2010-07-28 | Immunocore Ltd. | Cells expressing a modified t cell receptor |
| KR101704734B1 (ko) * | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| CA2673870A1 (en) | 2006-12-27 | 2008-07-10 | Emory University | Compositions and methods for the treatment of infections and tumors |
| NZ581468A (en) | 2007-06-25 | 2012-09-28 | Esbatech Alcon Biomed Res Unit | Methods of modifying antibodies, and modified antibodies with improved functional properties |
| PL2307458T3 (pl) | 2008-06-25 | 2018-08-31 | Esbatech, An Alcon Biomedical Research Unit Llc | Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała |
| PL2307455T3 (pl) | 2008-06-25 | 2017-09-29 | Esbatech, An Alcon Biomedical Research Unit Llc | Optymalizacja rozpuszczalności cząsteczek immunowiążących |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| EP2614143B1 (en) | 2010-09-08 | 2018-11-07 | Baylor College Of Medicine | Immunotherapy of non-small lung cancer using genetically engineered gd2-specific t cells |
| EP3692794A1 (en) | 2011-09-16 | 2020-08-12 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| US9175082B2 (en) * | 2012-05-31 | 2015-11-03 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| EP3467124A1 (en) * | 2012-06-06 | 2019-04-10 | Fundació Institut de Recerca Biomèdica IRB (Barcelona) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis |
| IL298125A (en) * | 2013-02-26 | 2023-01-01 | Memorial Sloan Kettering Cancer Center | Preparations and methods for immunotherapy |
| HK1218549A1 (zh) | 2013-06-26 | 2017-02-24 | Numab Therapeutics AG | 新型抗体框架 |
| WO2015038538A1 (en) | 2013-09-10 | 2015-03-19 | Medimmune, Llc | Compositions and methods for treating sepsis |
| WO2015080981A1 (en) | 2013-11-27 | 2015-06-04 | Baylor College Of Medicine | Csgp4-specific chimeric antigen receptor for cancer |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| CN122399016A (zh) * | 2014-03-15 | 2026-07-17 | 诺华股份有限公司 | 使用嵌合抗原受体治疗癌症 |
| WO2015188141A2 (en) * | 2014-06-06 | 2015-12-10 | Memorial Sloan-Kettering Cancer Ceneter | Mesothelin-targeted chimeric antigen receptors and uses thereof |
| CN106604933B (zh) * | 2014-07-11 | 2021-08-10 | 文塔纳医疗系统公司 | 抗pd-l1抗体及其诊断用途 |
| WO2016034666A1 (en) | 2014-09-04 | 2016-03-10 | Cellectis | Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy |
| ES2851123T1 (es) | 2014-09-26 | 2021-09-03 | Baylor College Medicine | Receptores quiméricos de antígeno específicos de glipicano-3 para inmunoterapia adoptiva |
| US20170335290A1 (en) | 2014-10-31 | 2017-11-23 | Baylor College Of Medicine | Survivin specific t-cell receptor targeting tumor but not t cells |
| RU2017125531A (ru) | 2014-12-19 | 2019-01-21 | Дана-Фарбер Кэнсер Инститьют, Инк. | Химерные антигенные рецепторы и способы их применения |
| GB201506642D0 (en) | 2015-04-20 | 2015-06-03 | Ucl Business Plc | T cell receptor |
| CN105331585A (zh) * | 2015-11-13 | 2016-02-17 | 科济生物医药（上海）有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| EP4086285A1 (en) | 2016-02-25 | 2022-11-09 | Cell Medica Switzerland AG | Binding members to pd-l1 |
-
2017
- 2017-02-24 EP EP21209739.8A patent/EP4086285A1/en not_active Withdrawn
- 2017-02-24 US US16/079,210 patent/US11434294B2/en active Active
- 2017-02-24 CN CN201780012727.3A patent/CN108699153B/zh not_active Expired - Fee Related
- 2017-02-24 RU RU2018128464A patent/RU2018128464A/ru not_active Application Discontinuation
- 2017-02-24 SG SG11201807188VA patent/SG11201807188VA/en unknown
- 2017-02-24 AU AU2017223846A patent/AU2017223846A1/en not_active Abandoned
- 2017-02-24 CN CN201780012682.XA patent/CN108884164B/zh not_active Expired - Fee Related
- 2017-02-24 JP JP2018544554A patent/JP7080819B2/ja not_active Expired - Fee Related
- 2017-02-24 CN CN202211150762.0A patent/CN116082505A/zh active Pending
- 2017-02-24 RU RU2018128462A patent/RU2018128462A/ru not_active Application Discontinuation
- 2017-02-24 CA CA3014001A patent/CA3014001A1/en active Pending
- 2017-02-24 KR KR1020187024673A patent/KR20180111870A/ko not_active Ceased
- 2017-02-24 EP EP17710091.4A patent/EP3420000A1/en not_active Withdrawn
- 2017-02-24 BR BR112018067698A patent/BR112018067698A2/pt not_active Application Discontinuation
- 2017-02-24 JP JP2018545230A patent/JP7082574B2/ja not_active Expired - Fee Related
- 2017-02-24 SG SG11201807187XA patent/SG11201807187XA/en unknown
- 2017-02-24 AU AU2017224843A patent/AU2017224843A1/en not_active Abandoned
- 2017-02-24 US US16/079,202 patent/US20190048085A1/en not_active Abandoned
- 2017-02-24 WO PCT/EP2017/054367 patent/WO2017144681A1/en not_active Ceased
- 2017-02-24 WO PCT/US2017/019301 patent/WO2017147383A1/en not_active Ceased
- 2017-02-24 CA CA3014067A patent/CA3014067A1/en active Pending
- 2017-02-24 EP EP17711573.0A patent/EP3420001B1/en active Active
- 2017-02-24 KR KR1020187027644A patent/KR20190003938A/ko not_active Ceased
- 2017-02-24 ES ES17711573T patent/ES2903408T3/es active Active
- 2017-02-24 BR BR112018067696A patent/BR112018067696A2/pt not_active Application Discontinuation
-
2022
- 2022-05-30 JP JP2022088103A patent/JP2022116230A/ja active Pending
- 2022-08-30 US US17/823,355 patent/US20230235061A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6681433B2 (ja) | Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト | |
| JP2022512653A5 (enExample) | ||
| JP2022122927A (ja) | Ｃｄ３結合抗体 | |
| JP2022512234A5 (enExample) | ||
| JP2017536341A5 (enExample) | ||
| JP2011509245A5 (enExample) | ||
| JP2021510710A5 (enExample) | ||
| JP2018183173A5 (enExample) | ||
| JP2009225799A5 (enExample) | ||
| JP2020525032A5 (enExample) | ||
| JP2019510733A5 (enExample) | ||
| JP2019524693A5 (enExample) | ||
| JP2017526339A5 (enExample) | ||
| JP2019513009A5 (enExample) | ||
| JP2021514973A5 (enExample) | ||
| JP2010500876A5 (enExample) | ||
| JP2018537421A (ja) | Ｇｉｔｒアゴニスト | |
| JP2024001073A5 (enExample) | ||
| JP2017519501A5 (enExample) | ||
| JP2017529838A5 (enExample) | ||
| PE20210554A1 (es) | Anticuerpos anti-cxcr5 y composiciones y usos de los mismos | |
| JP2013527761A5 (enExample) | ||
| JP2023540526A5 (enExample) | ||
| RU2021129189A (ru) | Антитела против фактора свертывания xi | |
| JP2017518040A5 (enExample) |